Investigational PPAR-γ agonists for the treatment of Type 2 diabetes

Expert Opinion on Investigational Drugs

Volumn 15, Issue 7, 2006, Pages 763-778

  Savkur, Rajesh S ^a   Miller, Anne R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Diabetes; Dyslipidaemia; Gene expression; Insulin resistance; Metabolic syndrome; Nuclear receptor; PPAR

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; GLUCOSE; INSULIN; ISOPROTEIN; NEW DRUG; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ANIMAL; ANTIBODY SPECIFICITY; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; DYSLIPIDEMIA; GENE EXPRESSION REGULATION; HAMSTER; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; METABOLISM; MOUSE; MOUSE MUTANT; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PHYSIOLOGY; RAT; REVIEW; SECRETION; SPRAGUE DAWLEY RAT; WEIGHT GAIN; ZUCKER RAT;

ADIPOCYTES; ANIMALS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CRICETINAE; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; DYSLIPIDEMIAS; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; LIPID METABOLISM; METABOLIC SYNDROME X; MICE; MICE, MUTANT STRAINS; MUSCLE CELLS; ORGAN SPECIFICITY; PPAR ALPHA; PPAR DELTA; PPAR GAMMA; PROTEIN ISOFORMS; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; WEIGHT GAIN;

EID: 33747196432     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.7.763     Document Type: Review

References (171)

1. WILD S, ROGLIC G, GREEN A et al.: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 27:1047-1053.
2. ZIMMET P, ALBERTI KG, SHAW J: Global and societal implications of the diabetes epidemic. Nature (2001) 414:782-787. (Pubitemid 34000780)
3. MOLLER DE, KAUFMAN KD: Metabolic syndrome: a clinical and molecular perspective. Ann. Rev. Med. (2005) 56:45-62. •• Excellent description of the metabolic syndrome.
4. GRUNDY SM, HANSEN B, SMITH SCJ et al.: Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation (2004) 109:551-556. (Pubitemid 38168522)
5. GERSHELL L: Type 2 diabetes market. Nat. Rev. Drug Discov. (2005) 4:367-368. (Pubitemid 40704113)
6. GRONEMEYER H, GUSTAFSSON JA, LAUDET V: Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. (2004) 3:950-964. •• Excellent review on the design of NR modulators.
7. MANGELSDORF DJ, THUMMEL C, BEATO M et al.: The nuclear receptor superfamily: the second decade. Cell (1995) 83:835-839. (Pubitemid 126663112)
8. FRANCIS GA, FAYARD E, PICARD F et al.: Nuclear receptors and the control of metabolism. Ann. Rev. Physiol. (2003) 65:261-311. •• Describes the NRs that regulate metabolism.
9. AUWERX J, BAULIEU E, BEATO M et al.: A unified nomenclature system for the nuclear receptor superfamily. Cell (1999) 97:161-163. (Pubitemid 29194267)
10. ISSEMANN I, GREEN S: Activation of a member of the steroid hormone receptor by peroxisome proliferators. Nature (1990) 347:645-650. (Pubitemid 20356241)
11. DREYER C, KREY G, KELLER H et al.: Control of peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell (1992) 68:879-887.
12. KLIEWER SA, XU HE, LAMBERT MH et al.: Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog. Horm. Res. (2001) 56:239-263. •• Excellent review on PPAR biology.
13. ZHU Y, ALVARES K, HUANG Q et al.: Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J. Biol. Chem. (1993) 268:26817-26820. (Pubitemid 24006385)
14. TONTONOZ P, HU E, GRAVES RA et al.: mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. (1994) 8:1224-1234. (Pubitemid 2102252)
15. KLIEWER SA, FORMAN BM, BLUMBERG B et al.: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA (1994) 91:7355-7359. (Pubitemid 24226862)
16. CHENG PT, MUKHERJEE R: PPARs as targets for metabolic and cardiovascular diseases. Mini Rev. Med. Chem. (2005) 5:741-753. •• Good description of why the PPARs are ideal targets for metabolic diseases.
17. WILLSON TM, BROWN PJ, STERNBACH DD et al.: The PPARs: from orphan receptors to drug discovery. J. Med. Chem. (2000) 43:527-550. •• Excellent review describing the PPARs.
18. BERGER JP, AKIYAMA TE, MEINKE PT: PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. (2005) 26:244-251. •• Well written review on why the PPARs are excellent targets for metabolic diseases.
19. RAM VJ: Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation. Prog. Drug Res. (2003) 60:93-132. (Pubitemid 36546179)
20. RAM VJ: Therapeutic significance of peroxisome proliferator-activated receptor modulators in diabetes. Drugs Today (Barc.) (2003) 39:609-632. (Pubitemid 37295516)
21. STAELS B, FRUCHART JC: Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes (2005) 54:2460-2470. •• Excellent description on the therapeutic potential of PPAR ligands.
22. BURRIS TP: The nuclear receptor superfamily. In: Nuclear Receptors and Genetic Disease, Burris TP, McCabe ERB (Eds), Academic Press, San Diego, USA (2001):1-57.
23. CASTILLO G, BRUN RP, ROSENFIELD JK et al.: An adipogenic cofactor bound by the differentiation domain of PPARγ EMBO J. (1999) 18:3676-3687. (Pubitemid 29308847)
24. BERGER J, MOLLER DE: The mechanism of action of PPARs. Ann. Rev. Med. (2002) 53:409-435. •• Excellent review describing the mechanism of PPARs.
25. KLIEWER SA, UMESONO K, NOONAN DJ et al.: Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature (1992) 358:771-774.
26. MANGELSDORF DJ, EVANS RM: The RXR heterodimers and orphan receptors. Cell (1995) 83:841-850. (Pubitemid 26006526)
27. SHER T, YI HF, McBRIDE OW et al.: cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry (1993) 32:5598-5604. (Pubitemid 23178525)
28. GUAN Y, ZHANG Y, DAVIS L et al.: Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am. J. Physiol. (1997) 273:F1013-F1022. (Pubitemid 127752137)
29. GOTTLICHER M, WIDMARK E, LI Q et al.: Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA (1992) 89:4653-4657.
30. CHINETTI G, GRIGLIO S, ANTONUCCI M et al.: Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. (1998) 273:25573-25580. (Pubitemid 28475776)
31. BRAISSANT O, FOUFELLE F, SCOTTO C et al.: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology (1996) 137:354-366. (Pubitemid 26005011)
32. AUBOEUF D, RIEUSSET J, FAJAS L et al.: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes (1997) 46:1319-1327.
33. INOUE I, SHINO K, NOJI S et al.: Expression of peroxisome proliferator-activated receptor α (PPAR α) in primary cultures of human vascular endothelial cells. Biochem. Biophys. Res. Commun. (1998) 246:370-374. (Pubitemid 28412605)
34. STAELS B, KOENIG W, HABIB A et al.: Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature (1998) 393:790-793. (Pubitemid 28299490)
35. PALMER CN, HSU MH, GRIFFIN KJ et al.: Peroxisome proliferator activated receptor-α expression in human liver. Mol. Pharmacol. (1998) 53:14-22. (Pubitemid 28068368)
36. LAWRENCE JW, LI Y, CHEN S et al.: Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) α. PPAR α fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression. J. Biol. Chem. (2001) 276:31521-31527. (Pubitemid 37384794)
37. CHINETTI G, LESTAVEL S, BOCHER V et al.: PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. (2001) 7:53-58. (Pubitemid 32095642)
38. MARTIN G, SCHOONJANS K, LEFEBVRE AM et al.: Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators. J. Biol. Chem. (1997) 272:28210-28217. (Pubitemid 27517759)
39. MOTOJIMA K, PASSILLY P, PETERS JM et al.: Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner. J. Biol. Chem. (1998) 273:16710-16714. (Pubitemid 28311694)
40. BRADY PS, MARINE KA, BRADY LJ et al.: Co-ordinate induction of hepatic mitochondrial and peroxisomal carnitine acyltransferase synthesis by diet and drugs. Biochem. J. (1989) 260:93-100. (Pubitemid 19139902)
41. MASCARO C, ACOSTA E, ORTIZ JA et al.: Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor. J. Biol. Chem. (1998) 273:23786-23792. (Pubitemid 28176129)
42. KELLY LJ, VICARIO PP, THOMPSON GM et al.: Peroxisome proliferator- activated receptors γ and α mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression. Endocrinology (1998) 139:4920-4927. (Pubitemid 28533438)
43. LEONE TC, WEINHEIMER CJ, KELLY DP: A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders. Proc. Natl. Acad. Sci. USA (1999) 96:7473-7478. (Pubitemid 29299686)
44. KERSTEN S, SEYDOUX J, PETERS JM et al.: Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J. Clin. Invest. (1999) 103:1489-1498.
45. LEE SS, PINEAU T, DRAGO J et al.: Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. (1995) 15:3012-3022.
46. PETERS JM, HENNUYER N, STAELS B et al.: Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice. J. Biol. Chem. (1997) 272:27307-27312. (Pubitemid 27452695)
47. AOYAMA T, PETERS JM, IRITANI N et al.: Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα). J. Biol. Chem. (1998) 273:5678-5684. (Pubitemid 28124039)
48. WATTS GF, DIMMITT SB: Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr. Opin. Lipidol. (1999) 10:561-574. (Pubitemid 30064026)
49. HOLNESS MJ, SMITH ND, GREENWOOD GK et al.: Acute (24 h) activation of peroxisome proliferator-activated receptor-α (PPARα) reverses high-fat feeding-induced insulin hypersecretion in vivo and in perifused pancreatic islets. J. Endocrinol. (2003) 177:197-205. (Pubitemid 36656392)
50. SUGDEN MC, HOLNESS MJ: Potential role of peroxisome proliferator- activated receptor-α in the modulation of glucose-stimulated insulin secretion. Diabetes (2004) 53:S71-S81. (Pubitemid 38168696)
51. YE JM, DOYLE PJ, IGLESIAS MA et al.: Peroxisome proliferator-activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-γ activation. Diabetes (2001) 50:411-417. (Pubitemid 32127300)
52. GUERRE-MILLO M, GERVOIS P, RASPE E et al.: Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. (2000) 275:16638-16642. (Pubitemid 30398891)
53. KIM H, HALUZIK M, ASGHAR Z et al.: Peroxisome proliferator-activated receptor-α agonist treatment in a transgenic model of Type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes (2003) 52:1770-1778. (Pubitemid 36792469)
54. CHOU CJ, HALUZIK M, GREGORY C et al.: WY14,643, a peroxisome proliferator-activated receptor α (PPARα) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J. Biol. Chem. (2002) 277:24484-24489. (Pubitemid 34951973)
55. SCHMIDT A, ENDO N, RUTLEDGE SJ et al.: Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol. (1992) 6:1634-1641.
56. MUKHERJEE R, JOW L, NOONAN D et al.: Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J. Steroid Biochem. Mol. Biol. (1994) 51:157-166. (Pubitemid 24372859)
57. AMRI EZ, BONINO F, AILHAUD G et al.: Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors. J. Biol. Chem. (1995) 270:2367-2371.
58. LEIBOWITZ MD, FIEVET C, HENNUYER N et al.: Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Lett. (2000) 473:333-336. (Pubitemid 30249149)
59. WANG Y-X, LEE C-H, TIEP S et al.: Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell (2003) 113:159-170. (Pubitemid 36514968)
60. OLIVER WRJr, SHENK JL, SNAITH MR et al.: A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA (2001) 98:5306-5311. (Pubitemid 32397124)
61. TANAKA T, YAMAMOTO J, IWASAKI S et al.: Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. USA (2003) 100:15924-15929. (Pubitemid 38021091)
62. DRESSEL U, ALLEN TL, PIPPAL JB et al.: The peroxisome proliferator-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol. Endocrinol. (2003) 17:477-2493. (Pubitemid 37542211)
63. KRAMER DK, AL-KHALILI L, PERRINI S et al.: Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor δ. Diabetes (2005) 54:1157-1163. (Pubitemid 40446331)
64. APERLO C, POGNONEC P, SALADIN R et al.: cDNA cloning and characterization of the transcriptional activities of the hamster peroxisome proliferator-activated receptor haPPAR γ. Gene (1995) 162:297-302.
65. GREENE ME, BLUMBERG B, McBRIDE OW et al.: Isolation of the human peroxisome proliferator activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. (1995) 4:281-299.
66. ELBRECHT A, CHEN Y, CULLINAN CA et al.: Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ 1 and γ 2. Biochem. Biophys. Res. Commun. (1996) 224:431-437. (Pubitemid 26268204)
67. FAJAS L, AUBOEUF D, RASPE E et al.: The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem. (1997) 272:18779-18789. (Pubitemid 27318225)
68. FAJAS L, FRUCHART JC, AUWERX J: PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett. (1998) 438:55-60. (Pubitemid 28517834)
69. MUKHERJEE R, JOW L, CROSTON GE et al.: Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. J. Biol. Chem. (1997) 272:8071-8076. (Pubitemid 27137374)
70. RICOTE M, HUANG J, FAJAS L et al.: Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA (1998) 95:7614-7619. (Pubitemid 28293301)
71. TONTONOZ P, GRAVES RA, BUDAVARI AI et al.: Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR γ and RXR α. Nucleic Acids Res. (1994) 22:5628-5634.
72. TONTONOZ P, HU E, SPIEGELMAN BM: Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor. Cell (1994) 79:1147-1156.
73. TONTONOZ P, HU E, DEVINE J et al.: PPAR γ 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol. Cell. Biol. (1995) 15:351-357. (Pubitemid 24379933)
74. SCHOONJANS K, WATANABE M, SUZUKI H et al.: Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J. Biol. Chem. (1995) 270:19269-19276.
75. COLLINS AR, MEEHAN WP, KINTSCHER U et al.: Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arteriosc. Thromb. Vasc. Biol. (2001) 21:365-371. (Pubitemid 32199117)
76. LI AC, BROWN KK, SILVESTRE MJ et al.: Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. (2000) 106:523-531. (Pubitemid 30666385)
77. CORTI R, OSENDE JI, FALLON JT et al.: The selective peroxisomal proliferator-activated receptor-γ agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. J. Am. Coll. Cardiol. (2004) 43:464-473. (Pubitemid 38167710)
78. MILES PD, ROMEO OM, HIGO K et al.: TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes (1997) 46:1678-1683. (Pubitemid 27456397)
79. STEPPAN CM, BAILEY ST, BHAT S et al.: The hormone resistin links obesity to diabetes. Nature (2001) 409:307-312. (Pubitemid 32151228)
80. YU JG, JAVORSCHI S, HEVENER AL et al.: The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and Type 2 diabetic subjects. Diabetes (2002) 51:2968-2974.
81. MAEDA N, TAKAHASHI M, FUNAHASHI T et al.: PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes (2001) 50:2094-2099. (Pubitemid 33643677)
82. ZIERATH JR, RYDER JW, DOEBBER T et al.: Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARγ agonist) action. Endocrinology (1998) 139:5034-5041. (Pubitemid 28533451)
83. YONEMITSU S, NISHIMURA H, SHINTANI M et al.: Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes (2001) 50:1093-1101. (Pubitemid 32374540)
84. AL-KHALILI L, FORSGREN M, KANNISTO K et al.: Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor γ co-activator 1. Diabetologia (2005) 48:1173-1179. (Pubitemid 40909654)
85. RANGWALA SM, LAZAR MA: Peroxisome proliferator-activated receptor γ in diabetes and metabolism. Trends Pharmacol. Sci. (2004) 25:331-336. •• Describes the role of PPAR-γ in diabetes and metabolic diseases.
86. WILLSON TM, LAMBERT MH, KLIEWER SA: Peroxisome proliferator-activated receptor γ and metabolic disease. Ann. Rev. Biochem. (2001) 70:341-347. •• Excellent review describing the role of PPAR-γ in diabetes and metabolic diseases.
87. MARTIN G, SCHOONJANS K, STAELS B et al.: PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis (1998) 137S:S75-S80. (Pubitemid 28294211)
88. PICARD F, AUWERX J: PPARγ and glucose homeostasis. Ann. Rev. Nutr. (2002) 22:167-197. •• Review elucidating the role of PPAR-γ in maintaining glucose homeostasis.
89. KIM JK, FILLMORE JJ, GAVRILOVA O et al.: Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes (2003) 52:1311-1318. •• Excellent work describing the effects of PPAR-γ agonists in fatless mice. (Pubitemid 36666182)
90. CHAO L, MARCUS-SAMUELS B, MASON MM et al.: Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. (2000) 106:1221-1228. (Pubitemid 30943947)
91. SALTIEL AR, OLEFSKY JM: Thiazolidinediones in the treatment of insulin resistance and Type II diabetes. Diabetes (1996) 45:1661-1669. (Pubitemid 26398943)
92. VASUDEVAN AR, BALASUBRAMANYAM A: Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol. Ther. (2004) 6:850-863. •• Comprehensive review on TZDs.
93. DIAMANT M, HEINE RJ: Thiazolidinediones in Type 2 diabetes mellitus: current clinical evidence. Drugs (2003) 63:1373-1405. (Pubitemid 36776093)
94. GALE EAM: Lessons from the glitazones: a story of drug development. Lancet (2001) 357:1870-1875. (Pubitemid 32539124)
95. ARONOFF S, ROSENBLATT S, BRAITHWAITE S et al.: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with Type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care (2000) 23:1605-1611. (Pubitemid 30812632)
96. ROSENBLATT S, MISKIN B, GLAZER NB et al.: The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with Type 2 diabetes mellitus. Coron. Artery Dis. (2001) 12:413-423. (Pubitemid 32664824)
97. WAGSTAFF AJ, GOA KL: Rosiglitazone: a review of its use in the management of Type 2 diabetes mellitus. Drugs (2002) 62:1805-1837. (Pubitemid 34948176)
98. PHILLIPS LS, GRUNBERGER G, MILLER E et al.: Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with Type 2 diabetes. Diabetes Care (2001) 24:308-315. (Pubitemid 32119130)
99. LEBOVITZ HE, DOLE JF, PATWARDHAN R et al.: Rosiglitazone monotherapy is effective in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. (2001) 86:280-288. (Pubitemid 32109807)
100. PARULKAR AA, PENDERGRASS ML, GRANDA-AYALA R et al.: Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med. (2001) 134:61-71. (Pubitemid 32037344)
101. HAFFNER SM, GREENBERG AS, WESTON WM et al.: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation (2002) 106:679-684. (Pubitemid 34851926)
102. GOLDBERG RB, KENDALL DM, DEEG MA et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care (2005) 28:1547-1554. (Pubitemid 40923063)
103. HUSSEIN Z, WENTWORTH JM, NANKERVIS AJ et al.: Effectiveness and side effects of thiazolidinediones for Type 2 diabetes: real-life experience from a tertiary hospital. Med. J. Aust. (2004) 181:536-539. (Pubitemid 39545628)
104. NESTO RW, BELL D, BONOW RO et al.: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care (2004) 27:256-263. (Pubitemid 38196741)
105. MUDALIAR S, CHANG AR, HENRY RR: Thiazolidinediones, peripheral edema, and Type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr. Pract. (2003) 9:406-416.
106. PAGE RLI, GOZANSKY WS, RUSCIN JM: Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Pharmacotherapy (2003) 23:945-954. (Pubitemid 36875678)
107. DIGMAN C, KLEIN AK, PITTAS AG: Leukopenia and thrombocytopenia caused by thiazolidinediones. Ann. Intern. Med. (2005) 143:465-466. (Pubitemid 41338946)
108. FONSECA V: Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am. J. Med. (2003) 115:42S-48S.
109. CHENG AYY, FANTUS IG: Thiazolidinedione-induced congestive heart failure, Ann. Pharmacother. (2004) 38:817-820. (Pubitemid 38509060)
110. COLUCCIELLO M: Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch. Opthalmol. (2005) 123:1273-1275. (Pubitemid 41316750)
111. KELLY IE, HAN TS, WALSH K et al.: Effects of a thiazolidinedione compound on body fat and fat distribution of patients with Type 2 diabetes. Diabetes Care (1999) 22:288-293. (Pubitemid 29056924)
112. NAKAMURA T, FUNAHASHI T, YAMASHITA S et al.: Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation - double-blind placebo-controlled trial. Diabetes Res. Clin. Pract. (2001) 54:181-190. (Pubitemid 33016325)
113. MIYAZAKI Y, MAHANKALI A, MATSUDA M et al.: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. (2002) 87:2784-2791. (Pubitemid 34655345)
114. ZHANG H, ZHANG A, KOHAN DE et al.: Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione- induced fluid retention. Proc. Natl. Acad. Sci. USA (2005) 102:9406-9411. (Pubitemid 40923576)
115. GUAN Y, HAO C, CHA DR et al.: Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat. Med. (2005) 11:861-866. (Pubitemid 41161118)
116. ARAKI K, YACHI M, HAGISAWA Y et al.: Antidiabetic characterization of CS-011: a new thiazolidinedione with potent insulin-sensitizing activity. Diabetes (2000) 49:ABS 105-P.
117. CHEN X, OSBORNE MC, RYBCZYNSKI PJ et al.: Pharmacological profile of a novel, non-TZD PPARγ agonist. Diabetes Obes. Metab. (2005) 7:536-546. (Pubitemid 41150427)
118. YAJIMA K, HIROSE H, FUJITA H et al.: Combination therapy with PPARγ and PPARα agonists increases glucose-stimulated insulin secretion in db/db mice. Am. J. Physiol. Endocrinol. Metab. (2003) 284:E966-E971. (Pubitemid 36444032)
119. CARMONA MC, LOUCHE K, NIBBELINK M et al.: Fenofibrate prevents rosiglitazone-induced body weight gain in ob/ob mice. Int. J. Obes. (2005) 29:864-871. (Pubitemid 40897026)
120. MURAKAMI K, TOBE K, IDE T et al.: A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ: effect of PPAR-α activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes (1998) 47:1841-1847. (Pubitemid 28549189)
121. WAGNER JA, CHUN X, RIPPLEY RK et al.: Single and multiple doses of MK-767 (KRP-297) reduce free fatty acids (FFA) and lipids in healthy subjects. Diabetes (2003) 52:ABS 588-P.
122. HENKE BR: Peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of Type 2 diabetes. J. Med. Chem. (2004) 47:4118-4127. (Pubitemid 39045415)
123. DEVASTHALE PV, CHEN S, JEON Y et al.: Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy] phenyl]methyl]glycine[Muraglitazar/ BMS-298585], a novel peroxisome proliferator-activated receptor α/γ dual agonist with efficacious glucose and lipid-lowering activities. J. Med. Chem. (2005) 48:2248-2250.
124. BUSE JB, RUBIN CJ, FREDERICH R et al.: Muraglitazar, a dual (α/γ) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with Type 2 diabetes. Clin. Ther. (2005) 27:1181-1195. (Pubitemid 41393913)
125. NISSEN SE, WOLSKI K, TOPOL EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. J. Am. Med. Assoc. (2005) 294:2581-2586. (Pubitemid 41697247)
126. LJUNG B, BAMBERG K, DAHLLOF B et al.: AZ 242, a novel PPARα/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J. Lipid Res. (2002) 43:1855-1863. (Pubitemid 35315803)
127. CRONET P, PETERSEN JF, FOLMER R et al.: Structure of the PPARα and -γ ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure (2001) 9:699-706. (Pubitemid 32772892)
128. OAKES ND, THALEN P, HULTSTRAND T et al.: Tesaglitazar, a dual PPARα/γ agonist, ameliorates glucose and lipid intolerance in obese Zucker rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 289:R938-R946. (Pubitemid 41397039)
129. FAGERBERG B, EDWARDS S, HALMOS T et al.: Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia (2005) 48:1716-1725. (Pubitemid 41317824)
130. GOLDSTEIN BJ, ROSENSTOCK J, ANZALONE D et al.: Tesaglitazar improves glucose and lipid abnormalities in patients with Type 2 diabetes. Diabetes (2005) 54:ABS 83-OR.
131. PRINCE M, SPICER K, CARO J et al.: Efficacy of LY519818, a novel non-TZD, PPARα dominant αγ dual agonist. Diabetes (2004) 53:ABS 139-OR.
132. REIFEL-MILLER A, OTTO K, HAWKINS E et al.: A peroxisome proliferator-activated receptor α/γ dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of Type 2 diabetes and dyslipidemia. Mol. Endocrinol. (2005) 19:1593-1605. (Pubitemid 41002988)
133. LIANG J, DEACON R, WALKER V et al.: PPARα/γ dual activation markedly improved glucose and lipid homeostasis and reduced body weight and food consumption in ob/ob mice. Diabetes (2004) 53:ABS 1333-P.
134. BOLOGNESE L, LI X, BOETTCHER B et al.: Anti-dyslipidemic and anti-diabetic effects of a PPARα/γ dual agonist in dyslipidemic hamsters. Diabetes (2004) 53:ABS 928-P.
135. LOWE DB, BIFULCO N, BULLOCK WH et al.: Substituted indanylacetic acids as PPAR-α-γ activators. Bioorg. Med. Chem. Lett. (2006) 16:297-301. (Pubitemid 41680617)
136. CHAKRABARTI R, MISRA P, VIKRAMADITHYAN RK et al.: Antidiabetic and hypolipidemic potential of DRF 2519 - a dual activator of PPAR-α and PPAR-γ. Eur. J. Pharmacol. (2004) 491:195-206. (Pubitemid 38609478)
137. LIU KG, LAMBERT MH, LEESNITZER LM et al.: Identification of a series of PPAR γ/δ dual agonists via solid-phase parallel synthesis. Bioorg. Med. Chem. Lett. (2001) 11:2959-2962. (Pubitemid 33000105)
138. ISHII S, SHIRAISHI M, SASAKI K et al.: A novel PPAR agonist, MCC-555, ameliorates endothelial cell dysfunction in vitro. Diabetes (2003):ABS 752-P.
139. UPTON R, WIDDOWSON PS, ISHII S et al.: Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. Br. J. Pharmcol. (1998) 125:1708-1714. (Pubitemid 29000817)
140. ETGEN GJ, OLDHAM BA, JOHNSON WT et al.: A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-α/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes (2002) 51:1083-1087. (Pubitemid 34438353)
141. ETGEN GJ, MANTLO N: PPAR ligands for metabolic disorders. Curr. Top. Med. Chem. (2003) 3:1649-1661.
142. GREGOIRE FM, RAKHMANOVA V, ZHANG F et al.: Effects of novel PPAR δ, PPAR dual δ/γ, and PPAR δ/γ/α (pan) agonists on PPAR-responsive genes in human adipocytes and macrophages. Diabetes (2005) 54:ABS 566-P.
143. SHANG Y, BROWN M: Molecular determinants for the tissue specificity of SERMs. Science (2002) 295:2465-2468. (Pubitemid 34270263)
144. SMITH CL, O'MALLEY BW: Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. (2004) 25:45-71. •• Excellent review on the mechanism underlying SNuRMs.
145. NETTLES KW, GREENE GL: Ligand control of coregulator recruitment to nuclear receptors. Ann. Rev. Physiol. (2005) 67:309-333. (Pubitemid 40404494)
146. RANGWALA SM, LAZAR MA: The dawn of the SPPARMs. Sci STKE (2002) 121/PE9:1-3.
147. ROCCHI S, PICARD F, VAMECQ J et al.: A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell (2001) 8:737-747. (Pubitemid 33030208)
148. LI Y, WANG Z, MOTANI A: T0903131 (T131): a selective modulator of PPARγ. Diabetes (2004) 53:ABS 659-P.
149. KERSEY K, FLOREN LC, PENDLETON B et al.: T0903131, a selective modulator of PPAR-γ activity, increases adiponectin levels in healthy subjects. Diabetes (2004) 53:ABS 656-P.
150. IMOTO H, IMAMIYA E, MOMOSE Y et al.: Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives. Chem. Pharm. Bull. (2002) 50:1349-1357. (Pubitemid 41702035)
151. ROSENSTOCK J, FLORES-LOZANO F, SCHWARTZ S et al.: MBX-102: a novel non-TZD insulin sensitizer that improves glycemic control without causing edema or weight gain in patients with Type 2 diabetes (T2DM) on concomitant insulin therapy. Diabetes (2005) 54:ABS 44-OR.
152. BERGER JP, PETRO AE, MacNAUL KL et al.: Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator. Mol. Endocrinol. (2003) 17:662-676. (Pubitemid 36403578)
153. LIU K., BLACK RM, ACTON JJI et al.: Selective PPARγ modulators with improved pharmacological profiles. Bioorg. Med. Chem. Lett. (2005) 15:2437-2440. (Pubitemid 40614966)
154. RIEUSSET J, TOURI F, MICHALIK L et al.: A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Mol. Endocrinol. (2002) 16:2628-2644. (Pubitemid 35266080)
155. LEHRKE M, PASCUAL G, GLASS CK et al.: Gaining weight: the Keystone Symposium on PPAR and LXR. Genes Dev. (2005) 19:1737-1742. (Pubitemid 41126910)
156. INOUE I, YOSHITOMI H, KASAI S et al.: Hypoglycemic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist, E3030, in db/db mice. Diabetes (2004) 53:ABS 544-P.
157. KASAI S, INOUE I, YOSHITOMI H et al.: Hypolipidemic effects of a novel dual PPAR α/γ agonist, E3030, in beagle dogs. Diabetes (2004) 53:ABS 553-P.
158. RANGWALA SM, RHOADES B, SHAPIRO JS et al.: Genetic modulation of PPARã phosphorylation regulates insulin sensitivity. Dev. Cell (2003) 5:657-663. (Pubitemid 37243053)
159. http://www.trustbasedmarketing.com/sm/news.1539/newsdetail.aspx Faxwatch news headlines: Merck ends Phase III programme for investigational diabetes treatment MK-767 and shares fall (21 November 2003).
160. http://www.bms.com/news/press/data/fg-press-release-5965.html Press release: Bristol-Myers Squibb statement on muraglitazar, an investigational oral treatment for Type 2 diabetes (27 October 2005),
161. http://www.bms.com/news/press/data/fg-press-release-6110.html Press release: Bristol-Myers Squibb statement on muraglitazar, an investigational oral treatment for Type 2 diabetes (22 December 2005).
162. http://en.sanofi-aventis.com Sanofi-Aventis - R&D portfolio (2005).
163. http://www.ono.co.jp Ono Pharmaceuticals annual report (2005).
164. http://www.gsk.com/financial/pp-pipeline-standard.htm GlaxoSmithKline product development pipeline (February 2006).
165. http://www.plexxikon.com/release-102804.shtml Press release: Plexxikon and Wyeth collaborate to develop novel treatments for diabetes and metabolic disorders (28 October 2004).
166. http://www.drreddys.com/newsroom/perlecan-home.htm Perlecan Pharma press release: India's first integrated drug development company (28 September 2005).
167. http://www.metabolex.com/MetaglidasenMBX-2044.html Metabolex product pipeline.
168. http://www.abgenomics.com/AntibodyX/AntibodyX.htm AbGenomics product pipeline.
169. http://www.novonordisk.com/press/news/news.asp?s Press release: facts about Novo Nordisk's clinical trials with ragaglitazar (26 July 2002).
170. http://www.takeda.com/press/05033001.htm Press release: discontinuation of development of antidiabetic agent TAK559 (30 March 2005).
171. http://www.astellas.com Investor relations: financial reports - R&D pipeline (7 November 2005).